OCEANSIX-FUTURE-PATHS-LT
15.2.2024 15:22:35 CET | Business Wire | Press release
oceansix Files Provisional Patent for Groundbreaking Packaging System
oceansix Future Paths Ltd. ("the Company" or "oceansix") is a publicly-traded Company on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0). oceansix is a technology and manufacturing company on an environmental mission, using plastic waste to create innovative products and build transformative businesses. The company is headquartered in Israel and operates a research and development centre and a production facility in Valencia, Spain.
oceansix Announces the Filing of a Provisional Patent Application for an Innovative Package System
With a continuous commitment to executing its business plan, oceansix marks a significant milestone in its journey towards revolutionising e-commerce packaging. Filed earlier this year, this invention is poised to set new standards in packaging efficiency and reusable systems.
Innovative Design for Sustainable Impact
The package, conceptualised by inventor Gat Ramon, features a unique design that addresses the pressing environmental concerns of traditional single-use packaging. It also solves the critical challenges companies face in ensuring the protection of their items during transit without adding excessive weight or bulk, thereby optimising shipping efficiency.
The packaging is also engineered to adapt to various product sizes, eliminating the need for excess cushioning materials and significantly reducing waste. With its ecological nature, it was designed to be manufactured from recycled materials and to be reused for up to 100 cycles; therefore, it fully aligns with oceansix's mission to foster sustainable practices across industries, particularly businesses where packaging and e-commerce are at their highest peak.
Addressing E-Commerce Challenges
oceansix's package is specifically designed to mitigate the environmental impact of e-commerce, targeting the waste generated by cardboard and plastic materials. The project aims to reduce CO2 emissions and enhance reverse logistics efficiency and cost-effectiveness, offering a scalable and automated-compatible solution that incorporates future features like real-time location tracking and unique identification with smart locking.
oceansix Joins TheCircularLab's goCircular Radar for Circular Economy Excellence
oceansix is honoured to announce its inclusion in the goCircular Radar by TheCircularLab, Europe's pioneering circular economy innovation centre. This distinction places oceansix on the map of leading startups in Europe's circular economy sector, highlighting the reusable packaging project's potential and opening avenues for collaboration.
oceansix Enhances Strategy with Expert Collaboration and New Incentive Options
In addition to our recent announcement about the packaging system, oceansix has granted 300,000 options to a consultant, with a strike price of CAD 0.29, valid for five years. This initiative is a key component of our broader strategy to collaborate with experts whose insights and expertise are vital in propelling our mission forward.
Join oceansix
oceansix invites stakeholders, partners, and the global community to join in its vision of creating impactful and sustainable solutions.
For more information about oceansix and its pioneering projects, please visit oceansix.com and connect with us on LinkedIn.
About oceansix
oceansix Future Paths Ltd. is a leader in developing radical, sustainable solutions and transforming waste into innovative products. Driven by a circular model and a vision to tackle some of Earth's most pressing challenges, oceansix combines advanced technology with sustainable practices to create meaningful solutions and successful global businesses.
Disclaimer
This press release may contain forward-looking statements based on current expectations and assumptions, subject to risks and uncertainties. Actual results may differ materially from those anticipated in these statements. oceansix assumes no obligation to update or revise any forward-looking information.
Approval & Accuracy
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215233336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom